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Background: Vaccines are important weapons in the fight against infectious diseases. The World Health Organization 
(WHO) Expanded Program on Immunization (EPI) has been extended to include recommendations for hepatitis 
B and Haemophilus influenzae type b (Hib) vaccinations. The WHO has recommended that combined vaccines be 
used where possible, to reduce the logistic costs of vaccine delivery. This paper reviews the efficacy, safety and cost- 
effectiveness of Tritanrix-HB/Hib, the only commercially available combined diphtheria, tetanus, whole cell pertussis, 
hepatitis B and conjugated Hib vaccine. 
Methods: The immunogenicity and reactogenicity results of five published clinical trials involving Tritanrix-HB/Hib 
in a variety of immunization schedules and countries were reviewed. Based on these data and cost-effectiveness 
studies, an assessment of its suitability for use in national immunization programs was made. 
Results: Tritanrix-HBiHib has shown excellent immunogenicity in clinical trials using a variety of schedules, with no 
reduced immunogenicity observed for any of the components of the combined vaccine. It has similar reactogenicity 
to DTPw vaccines alone. Pharmacoeconomic analyses have shown combined DTP-HB/Hib vaccines to be cost- 
effective compared to separate vaccines. 
Conclusions: Replacement of DTPw vaccination by Tritanrix-HB/Hib can be done without modifying the existing 
national immunization programs. This should facilitate widespread coverage of hepatitis B and Hib vaccinations and 
their rapid incorporation into the EPI. 
Int J Infect Dis 2003; 7: 143-151 
INTRODUCTION 
Infectious diseases constitute the leading cause of 
mortality and morbidity worldwide. Their impact varies 
widely among countries: in 1997, infectious and parasitic 
diseases were responsible for 43% of deaths in 
developing countries, but just 1% of fatalities in 
industrialized c0untries.l Vaccines are among the most 
effective weapons against infectious diseases, and 
effective vaccination programs can lead to dramatic 
decreases in mortality.2 One of the most spectacular 
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successes of vaccination was the global eradication of 
smallpox in 1980, after a campaign that began in 1967. 
However, there is still much to be done in implementing 
effective vaccination programs. The WHO has estimated 
that at least 2 million deaths among children under 
5 years old could be prevented each year, using existing 
vaccines.l 
A potential drawback of vaccination programs 
covering a wide range of diseases is that such programs 
could comprise large numbers of injections. A common 
strategy to reduce the number of injections needed is 
the use of combined vaccines, in which a single injection 
contains more than one antigen.3,4 Combined vaccines 
in widespread use include diphtheria, tetanus and 
pertussis (DTP) vaccine, and measles, mumps and rubella 
(MMR) vaccine. There are many advantages of com- 
bining vaccines in this way, as not only does it reduce 
discomfort for patients by sparing them multiple in- 
jections, but it also reduces some logistic costs linked to 
factors such as fewer clinic visits, syringes and needles, 
and a reduced requirement for cold storage of vaccines.5 
Moreover, when vaccinations are given separately, there 
is greater scope for missed doses6 so combined vaccines 
can also increase compliance, and hence the overall 
effectiveness of vaccination programs. 
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Combined DTP vaccines have been in widespread 
use since the 1940s. Today, global DTP coverage is 
estimated to exceed 8O%;7 this is a consequence of 
the fact that DTP is a mandatory component of most 
immunization programs. DTPw has been shown to be 
the most cost-effective means of pertussis prevention, 
provided that an effective whole cell vaccine is used 
with high coverage.8 Combining new vaccinations with 
DTP vaccine would therefore facilitate their inclusion in 
vaccination programs. However, before vaccines can 
be combined in the same injection, it is essential to 
demonstrate that the new combined vaccine does not 
adversely affect the immunogenicity of any of the com- 
ponents or lead to increased reactogenicity. 
EPIDEMIOLOGY 
Diphtheria was responsible for a substantial burden of 
disease before the introduction of routine vaccination 
against it. Large epidemics occurred in Europe during 
and after World War II, with an estimated 1 million cases 
and 50 000 deaths in 1943. Even recently, epidemics have 
occurred where vaccination coverage has been poor, 
particularly in eastern Europe.9 However, the incidence 
of diphtheria has fallen dramatically since routine vac- 
cination was introduced in the 1940s and 195Os.lO 
Tetanus is more common in developing countries, 
where immunization is less widespread than in in- 
dustrialized countries, and is a significant cause of 
mortality and morbidity. The WHO has estimated that 
there were 410 000 deaths due to tetanus in 1998, of 
which only 1000 occurred in countries classified as 
having high income.‘l 
Worldwide, Bordetella pertussis causes some 
20-40 million cases of pertussis, 90% of which occur in 
developing countries, and an estimated 200 000-300 000 
deaths each year. Although pertussis may occur at any 
age, most cases of serious disease and the majority of 
deaths are observed in early infancy. The introduction of 
routine vaccination against pertussis has dramatically 
reduced its public health impact.12,i3 When routine 
vaccination was withdrawn in the UK, Sweden and 
Japan because of concerns about the reactogenicity of 
the vaccine, a resurgence of the disease was seen.14-i6 
Hepatitis B (HB) is a widespread disease. More than 
2 billion people worldwide have evidence of past or 
current HB virus (HBV) infection, and more than 350 
million are chronic carriers of the virus.] Many chronic 
carriers of HBV develop cirrhosis and hepatocellular 
carcinoma, leading to substantial mortality.17-lg Overall, 
about 1 million people die each year as a result of HBV 
infectionzO HBV can be transmitted by a variety of 
routes, such as from mother to child (perinatal trans- 
mission), household contact with highly infectious 
individuals (horizontal transmission), sexual contact, or 
blood contact (e.g. needle sharing by intravenous drug 
users, or needlestick injuries to health care workers). 
The most important mode of transmission depends to 
some extent on prevalence rates. In countries with high 
HBV seroprevalence, perinatal transmission is common, 
whereas sexual transmission tends to be more important 
in countries with low HBV seroprevalence.21.22 
When HB vaccination was first introduced, it tended 
to be used only for individuals considered to be at high 
risk. However, that strategy has failed to control the 
disease in countries where it has been practiced,20 so it 
is now recommended that all infants be vaccinated 
against HBV. It has been clearly demonstrated that 
mass HB vaccination programs can dramatically reduce 
carrier rates. In Taiwan, where a nationwide program of 
HB vaccination began in 1984, the seroprevalence of 
HBV surface antigen (HBsAg) in children fell from 
9.8% in 1984 to only 1.3% in 1994.23 Moreover, there is 
evidence from Taiwan that such vaccination can be 
effective in reducing the incidence of hepatocellular 
carcinoma.“4,25 Similar beneficial effects have been 
observed in Italy.26 
Haemophilus injluenzae type b (Hib) is a Gram- 
negative bacterium responsible for a substantial burden 
of disease in industrialized and developing countries, 
causing about 3 million cases of serious disease and 
400 000-700 000 deaths annually in young children.27 It 
can cause various diseases, including meningitis and 
pneumonia. 28 Meningitis caused by Hib can have severe 
neurologic sequelae, even when promptly treated with 
appropriate antibiotics. 2g The burden of Hib disease in 
Latin America30 and Asia31,32 has recently been reviewed. 
In Latin America, the overall annual incidence of Hib 
meningitis in children under 5 years old was 35/100 000, 
which is similar to that in industrialized countries before 
the routine use of Hib vaccination, and translates into 
about 20 000 cases of Hib meningitis annually in the 
region. Overall, Hib disease was responsible for an 
annual burden of about 5000 deaths and 4800 children 
with serious sequelae in the region.30 In Asia, Hib was 
the most commonly isolated pathogen in children with 
bacterial meningitis. 31 Using a hypothetical model, it was 
estimated that 87% of cases of Hib deaths could be 
prevented by vaccination.33 
Because of the high burden of disease caused by 
Hib, even with the availability of antibiotic treatment, it 
is highly desirable that children be protected against Hib 
infection by vaccination. Vaccination programs can be 
extremely effective in preventing Hib infection. The 
incidence of invasive H. influenzae infection in children 
aged less than 5 years fell by 97% during the period 
1987-97 in the USA, where routine vaccination with Hib 
conjugate vaccines was introduced in 1988.34 There is 
also evidence that Hib vaccination can be effective in 
preventing invasive disease in developing countries.35,36 
WHO VACCINATION RECOMMENDATIONS 
Because vaccines represent an extremely effective and 
even cost-effective method of reducing the burden of 
disease, the World Health Organization (WHO) takes 
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an active role in encouraging their use. The WHO 
Expanded Program on Immunization (EPI) was founded 
in 1974, and originally included vaccinations against 
polio, diphtheria, tetanus, pertussis, tuberculosis, and 
measles. The EPI has made substantial progress in 
increasing global vaccine coverage, and all six of the 
original EPI vaccines had a global coverage of at least 
80% by 1997.7 However, that global figure masks sub- 
stantial inequalities among countries. For example, cover- 
age with BCG vaccine in 1997 was 90% worldwide, but 
only 66% in the WHO African region.7 There is there- 
fore still substantial room for improvement in vaccination 
coverage, particularly in developing countries. 
Because of the substantial burden of disease caused 
by HBV, and because of the dramatic reduction in that 
burden that can result from mass vaccination programs, 
the WHO recommended adding HB to the EPI vaccines 
in 1992.37 They stressed that it was important to 
implement routine vaccination, because of the failure of 
the strategy of vaccinating only those considered at high 
risk, stating ‘Only by mass vaccination of infants with 
HB vaccine as part of the EPI would the burden of 
HB infection be significantly reduced globally.‘38 Their 
original targets were to introduce routine vaccination 
against HBV in countries with carrier rates of 8% or 
greater by 1995, and in all countries, irrespective of HBV 
prevalence, by 1997. Although those targets were not 
met in full, substantial progress has been made towards 
them. The number of countries practicing routine HB 
vaccination increased from 20 in 1990 to 80 in 1996,20 
and was over 13.5 by the end of 2001.37 HBV can be 
transmitted perinatally, and in countries where this is a 
common mode of transmission, such as in Asia, the 
WHO recommends that the first dose of HB vaccine be 
given as soon after birth as possible, and within 12 h at 
the latest. This dose can then be followed by a second 
HB vaccination dose between months 1 and 2.“g 
The US Centers for Disease Control have also 
recommended routine childhood vaccination against 
HBV40 The recommendation has been successfully 
implemented with coverage of three or more doses of 
HB of vaccine administered to infants in the USA 
increased from 8% in 1992 to 82% in 1996.41 
The WHO issued further recommendations for 
HB vaccination in 1996;42 these noted that combined 
vaccines lead to fewer clinic visits, fewer injections, 
and reduced logistic requirements. The WHO therefore 
recommended that the combined DTP-HB vaccine was 
an excellent choice for the inclusion of HB vaccine in 
vaccination programs. 
More recently, the WHO has recommended that 
vaccination against Hib should be included in routine 
infant immunization programs, as appropriate to national 
capacities and priorities. 27 Those recommendations noted 
that Hib conjugate vaccines given in infancy are effective 
in reducing the burden of Hib disease, and also that Hib 
vaccination may safely be given concurrently with other 
EPI vaccines. 
A COMBINED DTPW-HB/Hib 
VACCINE 
To facilitate the incorporation of Hib into immunization 
schedules, GlaxoSmithKline Biologicals has developed a 
combined diphtheria, tetanus, whole cell pertussis, HB 
and Hib vaccine from two vaccines that were already 
licensed: Tritanrix-HB, a quadrivalent DTPw-HB vaccine; 
and Hiberix, a monovalent Hib conjugate vaccine. Both 
products have been reviewed by the WHO and found to 
be acceptable for purchase by UN agencies. 
The vaccine is prepared by extemporaneously 
mixing Tritanrix-HB and Hiberix vaccines in the same 
syringe. The clinical development program of the 
vaccine has included a number of trials comparing the 
combined vaccine with separate administration of its 
two constituent vaccines, over a range of schedules. 
Tritanrix-HB was first licensed in 1996, and is 
currently approved in over 70 countries. It has a proven 
track record of good immunogenicity and reacto- 
genicity, as has been shown by many clinical studies. 
Those studies were done with a variety of schedules: 
3 4 and 5 months,43 2, 4 and 6 months,44 3, 4.5 and 
6’months4’ and 1.5,3.5 and 6 months, following a dose 
of HB vaccine at birth.46 In all those studies, the sero- 
protection rates for HBV exceeded 95%, as recom- 
mended by the WH0,s7 and immune responses to the 
other three components were also excellent. Reacto- 
genicity was similar to that seen for DTPw vaccines 
alone.47%48 Although mild fever was common, fever 
>39.5”C was rare. The range of different schedules used 
in the clinical studies shows that Tritanrix-HB can be 
used without having to modify the schedules routinely 
used in different national immunization programs. 
Hiberix was first approved in 1997, and is now 
licensed in over 60 countries. It has good immuno- 
genicity, and a good reactogenicity profile.49 
Tritanrix-HB/Hib is the only commercially available 
combined vaccine against diphtheria, tetanus, pertussis, 
HB and Hib. 
CLINICAL STUDIES OF THE 
DTP-HB/Hib VACCINE 
Tritanrix-HB and Hiberix have proven immunogenicity 
and tolerability when given separately, but it cannot 
automatically be assumed that the combined vaccine 
will therefore be immunogenic and have acceptable 
reactogenicity. Although combining vaccines has many 
advantages, such as reduced costs and increased 
convenience for patients and health care workers, there 
is always a possibility that the vaccine components will 
interact in such a way that the immunogenicity is 
reduced or the reactogenicity is increased. A program of 
clinical trials was therefore undertaken to investigate 
whether the combined DTPw-HB/Hib vaccine produced 
by combining the vaccines in the same syringe would 
also be immunogenic and well tolerated. 
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In general, the studies found that the combined 
vaccine was indeed immunogenic for all five com- 
ponents, with no increase in reactogenicity compared 
with the separate components. As with Tritanrix-HB, 
there was already a good immune response after the 
second dose, with the advantages that this brings to 
areas where rates of partial non-compliance are high. 
The combined vaccine was also compatible with a single 
dose of HB vaccine given at birth (in this case, subjects 
received a total of four doses of HB vaccine), as recom- 
mended by the WHO for areas of high seroprevalence. 
The results of the studies are described in detail below. 
IMMUNOGENICITY OF TRITANRIX-HB/Hib 
Two studies have compared primary vaccination courses 
of the combined DTPw-HB/Hib vaccine, prepared by 
reconstituting Hiberix with Tritanrix-HB, with the same 
vaccines given separately. Coovadia et also vaccinated 
120 healthy South African infants with Tritanrix-HB and 
Hiberix, either as separate injections or as a combined 
injection, with a schedule of 2,4 and 6 months of age. 
Riedemann et a151 studied 120 Chilean infants in a study 
with a similar design, but with the addition of a booster 
dose at 18 months. Neither study showed any difference 
between the two modes of administration, and both 
studies showed seroconversion rates of 100% for all 
five vaccine components (some seroconversion rates in 
the Chilean study were less than 100% after the third 
dose, but all were 100% after the booster). The studies 
therefore convincingly demonstrated that Hiberix and 
Tritanrix-HB could be combined in the same syringe 
without any loss of immunogenicity for any of the 
vaccine components. Again, both studies showed high 
seroconversion rates as early as after the second dose. 
The booster dose in the Chilean study led to dramatic 
increases in antibody titers, demonstrating that the 
immune system had been suitably primed by the earlier 
doses, which is likely to be indicative of long-term pro- 
tection. Figure 1 shows the rates of seroprotection in 
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Figure 1. Responses to hepatitis B vaccination at two different 
schedules. %SP, percentage of seroprotected subjects. “Prikasky 
and Bock.43 bRiedemann et aL5’ m, month. P, post dose. 
response to the HB component of the vaccine, in com- 
parison with the rates obtained in a separate study using 
separate and combined DTPw and HB vaccinations. A 
seroprotection rate of almost 95% was observed in the 
group who received the combined vaccine after two 
doses, compared to 66% when DTPw and Hiberix 
vaccines were administered separately.52 
In a study conducted in Lithuania, 120 healthy 
infants received Tritanrix-HB combined with one of two 
production lots of Hiberix. Vaccinations were given at 3, 
4.5 and 6 months of age. The study found no difference 
between the subjects receiving either of the two lots of 
Hiberix mixed with DTPw-HB, with seroconversion 
rates of 100% or close to 100% for all five components.52 
The DTPw-HBiHib combined vaccine is also 
compatible with a separate HB vaccination at birth. Win 
et a153 compared combined and separate administration 
of Tritanrix-HB and Hiberix in 269 healthy infants in 
Myanmar at a schedule of 1.5,3 and 5 months of age, 
after a single dose of HB vaccine at birth. Both modes 
of administration had excellent immunogenicity, with no 
significant difference between them. A similar study in 
the Philippiness4 included 148 healthy infants, and used 
a vaccination schedule of 6,10 and 14 weeks, following 
a single HB vaccination at birth. Again, the proportion 
of subjects with seroprotective titers after three doses 
was lOO%, or close to 100%) for all components, and did 
not differ significantly between the two modes of 
administration. 
The geometric mean antibody titers after vaccina- 
tion at the various schedules described above are shown 
in Figures 2-6. The seroconversion rates observed in the 
studies are shown in Table 1. They demonstrated that no 
reduced immunogenicity was observed for any of the 
components of the combined vaccine when Hiberix was 
added to Tritanrix-HB. There is also little difference in 
the immunogenicity of the vaccine among the schedules. 
Therefore, the vaccine is likely to be suitable for 
inclusion in national immunization programs without 
having to modify their existing immunization schedules.. 
REACTOGENICITY OF TRITANRIX-HB/Hib 
The reactogenicity of Tritanrix-HB/Hib has been 
compared, in a per dose analysis, with that of Tritanrix- 
HB and Hiberix injections given separately in two 
studies.50,51 Both studies found no difference between 
modes of administration in the incidence of systemic 
reactions (which were mostly mild or moderate). There 
was a trend towards a higher incidence of local reactions 
for the combined vaccine, which was statistically 
significant for redness in one study. However, since 
giving the Hib vaccine separately requires twice as many 
injections as giving the combined vaccine, the overall 
burden of local reactions was lower for the combined 
vaccine. This is well demonstrated by the study of Win 
et a1,53 where the overall incidence of injection site 
reactions was 38.5% in the group receiving the 
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Figure 2. Geometric mean titers (with 95% confidence intervals) of antidiphtheria antibody (anti-D GMT in IU/mL) at different 
schedules of DTPw-HB and Hiberix, separately and combined. 
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Figure 3. Geometric mean titers (with 95% confidence intervals) of antitetanus antibody (anti-T GMT in IUlmL) at different 
schedules of DTPw-HB and Hiberix, separately and combined. 
Anti-pertussis GMTs 
Mixed Separate 
1.5-3-5 (Myanmar) 
2-4-6 (South Africa) 
0 2-4-6 (Chile) 
0 6-10-14 (Philippines) 
n 3-4.5-6 (Lithuania lot OOlA44) 
3-4.5-6 (Lithuania lot 0012A41) 
Figure 4. Geometric mean titers (with 95% confidence intervals) of antipertussis antibody (GMT in EL.U/mL) at different schedules 
of DTPw-HB and Hiberix, separately and combined. 
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Figure 5. Geometric mean titers (with 95% confidence intervals) of anti-hepatitis B antibody (anti-HBs GMT in mlU/mL) at different 
schedules of DTPw-HB and Hiberix, separately and combined. alncluded a single dose of HBV at birth. 
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Figure 6. Geometric mean titers (with 95% confidence intervals) of anti-H. influenzae antibody (anti-PRP GMT in mg/L) at different 
schedules of DTPw-HB and Hiberix, separately and combined. 
combined DTPw-HB/Hib vaccine, but was 41.3% at the 
DTPw-HB site and 19.7% at the Hiberix site. Therefore, 
as the DTPw-HB and DTPw-HB/Hib injection sites 
account for a similar incidence of local reactions, having 
a separate Hiberix injection site is clearly an additional 
burden. In any case, local tolerability was good for both 
treatments, with a low incidence of severe injection site 
reactions. 
Usonis et a152 also found that the overwhelming 
majority of reactions after 358 doses of combined 
Tritanrix-HB/Hib vaccination were mild or moderate. 
There were no reports of fever higher than 39.5”C, 
and all symptoms resolved without major medical inter- 
vention. 
Other studies have compared the reactogenicity of 
the Tritanrix-HB/Hib combined vaccine with Tritanrix- 
HB and Hiberix given separately, after a single dose of 
HB vaccine at birth. At schedules of 1.5,3 and 5 months 
of age,53 and 6,10 and 14 weeks of age,54 there were no 
significant differences in reactogenicity between the 
different modes of administration, except for a higher 
incidence of fever (>37.5”C) in one study in the group 
receiving separate injections (65%) than in those 
receiving the combined injections (49%). Again, in both 
studies, the vaccine was generally well tolerated. 
In all studies, the reactogenicity of the combined 
DTPw-HB/Hib vaccine was similar to that seen for the 
DTPw-HB vaccine alone (Table 2). Indeed, the reacto- 
genicity of the combined DTPw-HB/Hib vaccine com- 
pares favorably with that reported for DTPw vaccine 
alone.47,48 
COST-EFFECTIVENESS 
An important consideration in vaccination programs, 
particularly in the developing world, is the cost- 
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Table 1. Seroconversiona rates (%) after vaccination at various schedules 
n Diphtheria Tetanus Pertussis HB Hib 
3,4 and 5 months 
Prikazsky and Bock43 
(Tritanrix-HB) 44 100.0 100.0 97.7 97.7 
2,4 and 6 months 
Aristegui et al44 
(Tritanrix-HB) 167 100.0 100.0 92.2 100.0 
Coovadia et a150 
(DTPw-HBIHib) 49 100.0 100.0 100.0 100.0 100.0 
Riedemann et a15’ 
(DTPw-HB/Hib) 41 97.6 100.0 97.6 97.6 100.0 
3, 4.5 and 6 months 
Usonis et al45 
(Tritanrix-HB) 91 98.9 100.0 100.0 100.0 - 
Usonis et al53 
(DTPw-HB-Hib) 113 99.1 100.0 99.1 100.0 100.0 
1.5, 3.5 and 6 months+ 
HBV at birth 
Chiu et al46 
(Tritanrix-HB) 50 100.0 100.0 98.0 98.0 
1.5, 3 and 5 months+ 
HBV at birth 
Win et aIS 
(DTPw-HB/Hib) 127 89.7 100.0 100.0 100.0 98.4 
6, 10 and 14 weeks+ 
HBV at birth 
Bravo et al54 
(DTPw-HB/Hib) 50 94.0 100.0 95.9 96.0 100.0 
aSeroconversion was defined as seroprotective antibody titers for diphtheria (~0.1 IU/mL), tetanus (20.1 IU/mL), hepatitis B (>I0 mlU/mL), and 
H. influenzae (~0.15 mg/L), and as 2 15 ELISA Units/mL for pertussis. 
Table 2. Reactogenicity of DTPw-HB, DTPw-HB/Hib, and DTPw vaccines 
Vaccines 
Pain severe 
Swelling >2cm 
Redness >2cm 
Fever >39.5”C 
DTPw-HB DTPw-HBIHib 
pooled data pooled data 
n=2161 n=2241 
46.0 46.0 
3.0 3.7 
38.0 29.0 
9.0 6.0 
44.0 32.0 
5.0 3.8 
40.0 43.0 
0.6 1.0 
DTPw 
Cody et aF7 
n= 15 752 
51.0 
- 
41 .o 
- 
38.0 
47.0 
DTPw 
Gustafsson et a148 
n =2000 
81.0 
78.0 
22.0 
67.0 
15.0 
90.0 
1.3 
effectiveness of vaccines. In general, vaccines constitute 
an extremely cost-effective method of reducing the 
burden of disease. Combined vaccines lead to lower 
costs of vaccination programs than separate vaccina- 
tions. This has been borne out by pharmacoeconomic 
analysis. For example, Hadler55 calculated that adding 
HB and Hib vaccine to the US childhood immunization 
schedule would cost $440-500 million if separate 
vaccinations were given, but only $280 million if a com- 
bined DTP-HB/Hib vaccine was used. Fendrick et als6 
have also found combined vaccines to be more 
attractive economically, using a decision analysis model, 
and that they are more cost-effective than many 
commonly used medical interventions. A recent model 
evaluated the costs of a combined DTPw-HB versus 
separate DTPw + HB vaccination strategy if imple- 
mented in three countries of intermediate to high 
endemicity. The results showed that there are significant 
benefits to be gained from a combined DTPw-HB 
vaccination strategy in terms of economic savings and 
averted chronic carriers in each of the three countries 
studied (Van Damme and Maes, personal communi- 
cation). 
CONCLUSIONS 
Despite the substantial progress that the EPI has made 
in improving health, there is no room for complacency. 
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Many deaths are still potentially preventable by 
vaccination. One of the ways in which the goal of routine 
infant vaccination against vaccine-preventable diseases 
can be achieved is the use of combined vaccines, which 
protect against several diseases in a single injection, 
thereby saving considerable resources when compared 
with separate injections. Tritanrix-HB/Hib is a valuable 
weapon in the fight against infectious diseases, as 
it provides simultaneous vaccine coverage against 
diphtheria, tetanus, pertussis, HBV, and Hib. Many 
studies have shown it to have excellent immunogenicity 
when used in a variety of schedules, together with 
reactogenicity similar to that of DTPw vaccine alone. 
Replacing standard DTP vaccines, which already have 
high coverage, with Tritanrix-HB/Hib would therefore 
help to increase coverage against HBV and Hib 
diseases, both of which are responsible for substantial 
mortality and morbidity worldwide. 
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